ISCT Webinar: Derivation, expansion and quality control of human mesenchymal stem cells for GMP-grade cell manufacturing in monolayer and suspension cultures
Sponsored by Miltenyi Biotec
Organized by the ISCT Asia Regional Executive Committee
- Date: Wednesday, October 26, 2016
Time: 06:00 PDT, 09:00 EDT, 15:00 CEST, 21:00 SGT
- Steve Oh, PhD, Director Stem Cell Bioprocessing & Institute Scientist, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore
- Kathrin Godthardt, Senior Scientist, R&D Department, Miltenyi Biotec, Germany
- Kah Yong Tan, PhD, Research Fellow, Bioprocessing Technology Institute, Agency for Science, Technology and Research, Singapore
About the Webinar:
Kathrin Godthardt: The demand for xeno-free and GMP-compliant production of clinical-scale mesenchymal stem cells (MSCs) and standardized quality control (QC) measures for cellular products is rising. Currently, a number of clinical phase II/III trials are registered, emphasizing the clinical relevance of mesenchymal stem cells. In this context, the use of fetal calf serum (FCS) is undesirable with regards to avoiding adverse events and minimizing lot-to-lot variations. Therefore, highly defined serum- and xeno-free culturing systems for MSC derivation and expansion are of great interest to ensure reliable and reproducible cell manufacturing processes. This webinar will focus on novel MSC culturing systems and workflows facilitating the derivation and expansion up to a clinically relevant scale of human MSCs including QC measures in order to determine the functionality of the cellular product.
Kah Yong Tan: Various serum-free medium formulations are currently available for mesenchymal stromal cell culture. These serum-free media are commonly reported to outperform serum-containing media for cell growth. However, not all medium formulations are alike, and growth performance can be cell- and medium-specific. Furthermore, serum-free media that support monolayer culture may be insufficient for microcarrier culture. This may impact future considerations for scale-up culture.
- Comparison of MSC culture systems
- Quality control measures to ensure MSC functionality
- GMP-compliant workflows for MSC derivation and expansion
- Serum-free media formulations can be cell-line specific
- Serum-free media may require optimization for microcarrier culture